81 related articles for article (PubMed ID: 17471168)
21. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.
Ngo MC; Ando J; Leen AM; Ennamuri S; Lapteva N; Vera JF; Min-Venditti A; Mims MP; Heslop HE; Bollard CM; Gottschalk S; Rooney CM
J Immunother; 2014 May; 37(4):193-203. PubMed ID: 24714353
[TBL] [Abstract][Full Text] [Related]
22. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
Turcanová V; Höllsberg P
J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
[TBL] [Abstract][Full Text] [Related]
23. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients.
Lutzky VP; Davis JE; Crooks P; Corban M; Smith MC; Elliott M; Morrison L; Cross S; Tscharke D; Panizza B; Coman W; Bharadwaj M; Moss DJ
Immunol Cell Biol; 2009; 87(6):481-8. PubMed ID: 19468283
[TBL] [Abstract][Full Text] [Related]
24. CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.
Tsang CW; Lin X; Gudgeon NH; Taylor GS; Jia H; Hui EP; Chan AT; Lin CK; Rickinson AB
J Virol; 2006 Aug; 80(16):8263-6. PubMed ID: 16873282
[TBL] [Abstract][Full Text] [Related]
25. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.
Voo KS; Fu T; Heslop HE; Brenner MK; Rooney CM; Wang RF
Cancer Res; 2002 Dec; 62(24):7195-9. PubMed ID: 12499257
[TBL] [Abstract][Full Text] [Related]
26. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals.
Iwai LK; Yoshida M; Sidney J; Shikanai-Yasuda MA; Goldberg AC; Juliano MA; Hammer J; Juliano L; Sette A; Kalil J; Travassos LR; Cunha-Neto E
Mol Med; 2003; 9(9-12):209-19. PubMed ID: 15208742
[TBL] [Abstract][Full Text] [Related]
27. MHC class II tetramers containing influenza hemagglutinin and EBV EBNA1 epitopes detect reliably specific CD4(+) T cells in healthy volunteers.
Ye M; Kasey S; Khurana S; Nguyen NT; Schubert S; Nugent CT; Kuus-Reichel K; Hampl J
Hum Immunol; 2004 May; 65(5):507-13. PubMed ID: 15172451
[TBL] [Abstract][Full Text] [Related]
28. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
29. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
Chiang AK; Tao Q; Srivastava G; Ho FC
Int J Cancer; 1996 Nov; 68(3):285-90. PubMed ID: 8903467
[TBL] [Abstract][Full Text] [Related]
30. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope.
Omiya R; Buteau C; Kobayashi H; Paya CV; Celis E
J Immunol; 2002 Aug; 169(4):2172-9. PubMed ID: 12165547
[TBL] [Abstract][Full Text] [Related]
32. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
[TBL] [Abstract][Full Text] [Related]
33. Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo.
Fu T; Voo KS; Wang RF
J Clin Invest; 2004 Aug; 114(4):542-50. PubMed ID: 15314691
[TBL] [Abstract][Full Text] [Related]
34. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine.
Lutzky VP; Corban M; Heslop L; Morrison LE; Crooks P; Hall DF; Coman WB; Thomson SA; Moss DJ
J Virol; 2010 Jan; 84(1):407-17. PubMed ID: 19846527
[TBL] [Abstract][Full Text] [Related]
35. Primary nasopharyngeal non-Hodgkin lymphoma and its relationship with Epstein-Barr virus infection.
Zhang B; Zong Y; He J; Zhong B; Lin S
Chin Med J (Engl); 2003 Jun; 116(6):913-7. PubMed ID: 12877806
[TBL] [Abstract][Full Text] [Related]
36. Immune response of mice to a latency membrane protein 2 multiepitope antigen of Epstein-Barr virus applied as DNA vaccine and/or peptide vaccine.
Li W; Chen Q; Chen H; Rao P; Xue X; Chen S; Zhu S; Zhang L
Acta Virol; 2013; 57(1):51-8. PubMed ID: 23530824
[TBL] [Abstract][Full Text] [Related]
37. A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes.
Hartman IZ; Kim A; Cotter RJ; Walter K; Dalai SK; Boronina T; Griffith W; Lanar DE; Schwenk R; Krzych U; Cole RN; Sadegh-Nasseri S
Nat Med; 2010 Nov; 16(11):1333-40. PubMed ID: 21037588
[TBL] [Abstract][Full Text] [Related]
38. HLA class I associations with EBV+ post-transplant lymphoproliferative disorder.
Jones K; Wockner L; Thornton A; Gottlieb D; Ritchie DS; Seymour JF; Kumarasinghe G; Gandhi MK
Transpl Immunol; 2015 Mar; 32(2):126-30. PubMed ID: 25731678
[TBL] [Abstract][Full Text] [Related]
39. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
40. Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes.
Levitsky V; Zhang QJ; Levitskaya J; Kurilla MG; Masucci MG
J Immunol; 1997 Dec; 159(11):5383-90. PubMed ID: 9548478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
